Pentaglobin (Human Normal Immunoglobulin)

Quick links

Choose a section

Quick links to important sections

Advertisements

Pentaglobin (Human Normal Immunoglobulin)

Advertisements
Advertisements

Overview of Pentaglobin (Human Normal Immunoglobulin)

Property Description
Active ingredient Human Normal Immunoglobulin (IgG, IgA, IgM)
Form Solution for infusion
Pharmacological class Immunoglobulin Preparation, Immune Modulator
Common use Providing passive immunization, supporting immune defense
Origin Human-derived, Plasma fractionation product

What Type of Medicine is Pentaglobin (Human Normal Immunoglobulin)?

Pentaglobin is a biological product and a specialized intravenous immunoglobulin (IVIg) preparation, classified within the pharmacological class of Immunoglobulin Preparations and Immune Modulators. The active ingredient, Human Normal Immunoglobulin, is a highly purified antibody concentrate sourced from pooled human plasma proteins, making it a human-derived blood product. This preparation is formulated as a solution for infusion for exclusive delivery via the intravenous (IV) route and is a prescription-only medicine. The importance of this class of therapy for immediate immune support is widely clinically recognized for patients who cannot mount their own effective antibody responses. This type of preparation provides a broad spectrum of protective antibodies.

Composition and Origin: Why is Pentaglobin Called "Polyvalent"?

This medicine is created through the rigorous process of plasma fractionation, ensuring that the resulting concentrate has a broad range of antibodies from diverse donor exposure. Pentaglobin is distinctively termed polyvalent because, unlike standard IVIg products, its formulation includes functional concentrations of Immunoglobulin A (IgA) and Immunoglobulin M (IgM) in addition to the predominant Immunoglobulin G (IgG). The quality of these plasma-derived products, including the specific immunoglobulin types they contain, is subject to high standards. This composition, with the inclusion of the pentameric IgM, provides a differentiating factor in acute immune support scenarios.

General Purpose: What Role Does This Immunoglobulin Play in Defense?

The primary general purpose of this therapy is to confer immediate passive immunization by instantly supplying protective antibodies to the recipient. This process rapidly increases the patient’s capacity for pathogen neutralization and supports essential immune defense mechanisms. A typical neutral use scenario for this drug is providing immediate, broad antibody coverage to an individual with severely compromised immune function, thereby enhancing the body’s ability to control systemic microbial threats. The administration of this polyvalent concentrate helps to restore and maintain crucial immune system balance.

Regulatory References

  1. WHO Essential Medicines List
Advertisements

What side effects are possible with Pentaglobin (Human Normal Immunoglobulin)?

Possible side effects and safety information

The safety profile of Human Normal Immunoglobulin is structured by regulatory documents based on the likelihood of adverse events and the body systems affected. The frequency of side effects is formally classified according to government guidelines.


Classification of Documented Adverse Reactions

Common adverse reactions (may affect up to 1 in 10 people) are typically transient and include symptoms like Headache, Fever (Pyrexia), Chills (rigors), Hypotension (low blood pressure), Tachycardia, Flushing, Nausea, and Vomiting. Reactions classified as Uncommon include generalized Hypersensitivity, Dizziness, and skin-related events such as Rash or Pruritus (itching).

Many of these non-serious effects may be related to the rate of infusion or may be more likely to occur during the initial phase of treatment or during dose escalation, as noted in official regulatory information.


Serious Safety Considerations and Constraints

The most serious, though rare or very rare, reactions documented in regulatory labeling include Anaphylactic shock and Thromboembolic events such as pulmonary embolism or deep vein thrombosis. Acute renal failure and Aseptic Meningitis Syndrome (AMS) are also listed as rare potential adverse effects.

Specific patient considerations are documented in the prescribing information. The medicine is contraindicated in individuals with known severe hypersensitivity to human immunoglobulins or in those with selective IgA deficiency who have pre-formed anti-IgA antibodies. Individuals with pre-existing renal impairment or risk factors for thrombosis (e.g., advanced age) are noted as requiring specific consideration.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose of Human Normal Immunoglobulin, typically linked to an excessively high volume or rapid infusion rate, is primarily associated with physiological issues resulting from volume and protein overload. Documented initial manifestations may include headache, flushing, nausea, and vomiting. Physiological signs can involve fluid retention and an increased blood viscosity, potentially leading to a transient increase in serum creatinine.

Severe or life-threatening outcomes officially cited in regulatory documents include circulatory overload and subsequent pulmonary edema. The hyperviscosity state documented in overdose situations is associated with an increased risk of thromboembolic events, such as acute renal failure, myocardial infarction, and cerebrovascular events.


When to Seek Urgent Help and Required Actions

The regulatory instruction for a suspected overdose is to interrupt or permanently stop the infusion immediately. Urgent medical attention must be sought for any manifestation of severe complications, such as signs of circulatory overload or suspected acute renal failure.

Management is defined as symptomatic and supportive treatment because official labeling states that no specific antidote is known. This care includes addressing volume complications with measures such as diuretics.


Population-Specific Overdose Considerations

Official documents highlight that the risk of severe outcomes, particularly acute renal failure, is increased in specific populations. These include elderly patients and individuals with pre-existing renal impairment or volume-sensitive cardiovascular conditions.

Advertisements

Therapeutic Uses of Pentaglobin (Human Normal Immunoglobulin)

What Pentaglobin (Human Normal Immunoglobulin) Treats: Main Uses and Benefits

The therapeutic application of this polyvalent immunoglobulin is used in situations involving certain distressing symptoms across conditions marked by severe deficiency or disruptive physiological activity. It is relevant in contexts marked by increased discomfort or tension.

It is commonly used to manage the symptoms of conditions involving profound antibody deficiency, such as recurrent, severe infections in primary immunodeficiencies. The therapy plays a role in managing these symptoms, and may assist with managing symptoms that create noticeable physiological strain by helping to supply protective antibodies. This support contributes to easing the overall symptom load by helping to maintain physiological stability.

Furthermore, it supports patient stability in acute scenarios like severe sepsis and septic shock, and may assist with managing the risk associated with rapid symptomatic changes in specific autoimmune disorders, including Immune Thrombocytopenia (ITP) and Kawasaki Disease. It assists with maintaining functional stability when symptoms are more noticeable, and may be relevant for easing the impact of long-term complications. This makes it relevant for managing high-risk immunosuppressed patient groups, such as those post-Hematopoietic Stem Cell Transplantation (HSCT).


Quick Fact: Relief for Recurrent Infections The medicine is commonly used to help manage symptoms that interfere with daily functioning across conditions characterized by periods of heightened infectious symptoms due to low protective antibodies.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Pentaglobin (Human Normal Immunoglobulin)?

Eligibility for Pentaglobin is defined by regulatory authorities based on a patient's immune status and pre-existing medical conditions.

Absolute Contraindications (Must Not Use)

  • Patients with known hypersensitivity to the active substance (human normal immunoglobulin).
  • Individuals with selective IgA deficiency who have formed antibodies against IgA.

Conditional Restrictions (Requires Caution/Monitoring) The medicine's use is restricted and requires careful consideration in high-risk populations, including:

  • Older Adults: Patients over 65 years are identified as being at higher risk for thromboembolic events and acute renal failure.
  • Renal or Metabolic Conditions: Caution is mandatory for patients with pre-existing renal insufficiency or risk factors such as diabetes mellitus and hypovolemia.
  • Pregnancy: Safety has not been established in controlled trials. Use is conditional on a formal risk/benefit assessment.

Use is established across all age groups from neonates through adults for the approved indications. The use during lactation is generally considered not to be harmful to the breastfed infant.

Advertisements

What should I know about interactions with other medicines?

Pentaglobin (Human Normal Immunoglobulin) Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Human Normal Immunoglobulin, based strictly on authoritative regulatory labeling. The known interactions relate primarily to the product's effect on the immune system and its influence on specific diagnostic procedures.

Category Interacting Entity Official Description of Interaction
Pharmacodynamic Interaction Live attenuated vaccines (e.g., Measles, Rubella, Mumps, Varicella) The passive transfer of antibodies may impair the efficacy of the vaccine by reducing the patient's expected immune response.
Administration Restriction Calcium gluconate Co-administration is prohibited in infants due to the potential for adverse reactions, according to regulatory documents.
Procedural Interference Serological Tests The transitory rise of passively transferred antibodies can result in misleading positive results in certain serological analyses, such as the direct antiglobulin test.

The most significant regulatory constraint involves administration timing: an interval of at least three months must elapse after administration before vaccination with live attenuated vaccines. For the measles vaccine, official documentation indicates that this separation may need to persist for up to one year to ensure an adequate immune response. This specialized interaction profile is characterized by immunological and age-specific regulatory constraints.

Advertisements

Mechanism of Action

Pentaglobin's action involves a dual-action mechanism influencing the immune system and circulating factors. It is an IgM-enriched formulation, differentiating its influence from standard immunoglobulin preparations. The mechanistic domains involve pathogen neutralization and immune regulation.


Pathogen Neutralization and Binding

This domain describes the direct properties of the immunoglobulins. The high content of IgM enhances complement system activation, facilitating the binding and removal of bacteria and other factors. The antibodies also directly bind and neutralize bacterial toxins and inflammatory mediators, influencing their systemic distribution and moderating physiological responses.


Immunomodulation and Signaling

This domain involves the regulatory effects on immune pathways and cells. Pentaglobin engages mechanisms that modulate cytokine production, such as increasing anti-inflammatory mediators like IL-10 and inhibiting pro-inflammatory ones like TNF-alpha and IL-6. This action influences feedback regulation within immune signaling, resulting in the modulation of targeted pathways and a shift toward regulated immune function within processes associated with dysregulated immune responses.

Advertisements

Dosage and Administration Information

The administration of Pentaglobin (Human Normal Immunoglobulin) is highly structured, adhering strictly to procedural guidelines. This medicine is provided as a 50 mg/ml solution for infusion and is intended exclusively for intravenous use. The use protocol precisely defines the volume of concentrate, the required frequency, and the specific delivery rate.

The standard administration pattern is differentiated by the usage context:

Usage Context Dosing Regimen (per kg body weight) Frequency Pattern
Severe Bacterial Infections 5 ml (0.25 g protein) daily Administered daily on 3 consecutive days
Immunoglobulin Substitution 3 - 5 ml (0.15 - 0.25 g protein) May be repeated at weekly intervals

For proper administration, the solution must be brought to room or body temperature prior to initiation. The product is administered undiluted and must not be mixed with other intravenous fluids, constituting a specific administrative constraint.

Infusion rates are strictly controlled and depend on the patient population. For adults and older children, the initial rate is set at 0.4 ml/kg body weight per hour. A distinctly faster rate of 1.7 ml/kg body weight per hour via an infusion pump is designated for neonates and infants, reflecting a key population-specific instruction. These procedural controls define the entirety of the standardized administrative protocol.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Pentaglobin (Human Normal Immunoglobulin)

Research evidence for this specialized immunoglobulin preparation, which is notable for containing Immunoglobulin G (IgG), Immunoglobulin A (IgA), and Immunoglobulin M (IgM), was studied for its application across different medical needs. The available data are drawn from clinical trials, meta-analyses, and broad experience with the intravenous immunoglobulin (IVIg) class.

Evidence for Use in Primary Antibody Deficiency

The research base supporting the evaluation of immunoglobulin in people with Primary Immunodeficiency (PID) includes many years of clinical experience and detailed observational settings evaluating daily-life functioning. Studies monitored both adults and children who have conditions marked by functional limitations where the body has impaired antibody production. The therapy research examined its use in long-term replacement protocols, monitoring the maintenance of target serum IgG concentrations over extended periods. The clinical role of immunoglobulin replacement therapy is broadly supported by long-standing consensus.

Evidence for Use in Severe Sepsis and Septic Shock

The polyvalent immunoglobulin was evaluated in research for its use in acute, critical medical situations, such as severe sepsis and septic shock. Research in this area primarily involved Randomized Controlled Trials (RCTs) and subsequent meta-analyses that combined data. These studies focused on outcomes related to physiological strain or stress, specifically measuring endpoints such as all-cause mortality and outcomes reflecting daily functioning or activity level, such as the time spent on a ventilator. Findings were mixed across the aggregated trials, meaning the results were not consistent in all studies. The evidence is limited for this specific application, and evidence quality varies across studies.

What Is Still Uncertain About Pentaglobin (Human Normal Immunoglobulin) Studies

Evidence highlights what is known — and what is still uncertain. The primary uncertainty across the research base is related to the specific contribution of the IgM and IgA enrichment. Comparative evidence is lacking from trials specifically designed to show whether the polyvalent composition was associated with different outcomes than standard IgG-only preparations in many of its studied uses.

Key Studies & References

  1. TGA Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)
  2. The clinical utility of intravenous immunoglobulin (IVIg) in hematological and autoimmune diseases: a comprehensive review
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pentaglobin (Human Normal Immunoglobulin) (FAQ)

Q: How quickly does Pentaglobin start working after the infusion?

Regulatory information indicates that the immunoglobulin is immediately and completely available in your bloodstream after the intravenous infusion. The process of the medicine distributing from the blood plasma into the rest of the body’s fluids to reach full balance typically takes around 3 to 5 days.

Q: How long does the effect of a Pentaglobin infusion typically last?

According to official product information, the component called human normal immunoglobulin has a half-life of about 27 days. This means that half of the medicine is still active in your system after approximately four weeks. However, the actual duration of the effect can vary between patients.

Q: Are there any long-term side effects linked to Pentaglobin use?

Regulatory documents guide the use of this type of medication in long-term replacement therapy for certain conditions. Official documents state that if the medicine is not showing a treatment effect after six months, its use should be re-evaluated.

Q: What happens if I miss a scheduled Pentaglobin treatment?

Official guidance for similar IVIg products suggests that a missed dose should be administered promptly. Following this, the standard treatment schedule should then be resumed.

Q: Is Pentaglobin safe to use during pregnancy?

Official product information states that safety for use in pregnant women has not been established through controlled clinical trials. Therefore, the medicine is only administered during pregnancy when the potential benefit is assessed against the potential risk.

Q: Can Pentaglobin treatment be stopped abruptly?

For conditions requiring long-term immune support, sudden discontinuation of the medicine may remove the immediate antibody support. Therefore, any decision regarding cessation of treatment is managed by the prescribing physician.

Q: Is there a risk of transmitting diseases from the plasma used to make Pentaglobin?

Regulatory documents describe the manufacturing procedures used to minimize the risk of pathogen transmission. The measures taken are established as effective for the removal or inactivation of enveloped viruses, such as HIV and Hepatitis B and C. However, these measures may be of limited use against non-enveloped viruses, such as Parvovirus B19 and Hepatitis A, according to official warnings.

Q: Can I drive or operate machinery after receiving Pentaglobin?

Official guidance indicates that side effects such as dizziness or nausea, which are documented potential effects, may temporarily affect the ability to drive or use machines. If a patient experiences any adverse reaction during or after the infusion, it is advised that these activities be avoided until the reaction has subsided.

Q: What is the maximum number of times a person can receive Pentaglobin?

The duration of treatment is determined entirely by the patient’s clinical status and how they respond to the therapy. For some conditions, treatment is administered in defined cycles, and official documents specify that the treatment should be re-evaluated if no clinical effect is observed after six months.

Q: Does the treatment cause tiredness or fatigue?

Fatigue (or tiredness) is listed as a potential side effect in the medicine's regulatory documents. Patients who experience severe or persistent symptoms should inform their healthcare professional.

Q: What should I do if the infusion site becomes painful or red?

Infusion site reactions, including pain, swelling, or redness, are documented as potential side effects in the medicine's regulatory information. These effects should be communicated to the healthcare professional managing the treatment.

Q: Does Pentaglobin contain sugar, sodium, or preservatives?

The official composition documents for the solution for infusion state that it contains both glucose (a form of sugar) and sodium. Official prescribing information notes that the presence of glucose is a consideration for patients with diabetes.

Q: If I have a history of autoimmune disease, can I still receive Pentaglobin?

Official indications for this class of medicine include the treatment of certain inflammatory and autoimmune conditions, such as Guillain Barré syndrome. The use of this drug is assessed based on the specific condition.

Q: How do I know if the Pentaglobin treatment is working for me?

For uses such as replacement therapy, the treatment’s effectiveness is often monitored by measuring the level of protective antibodies (IgG trough levels) in the blood and by tracking the frequency of infections. For other uses, the effect is assessed by the treating physician based on the patient's clinical response after each treatment cycle.

Q: Is it possible to have an allergic reaction to Pentaglobin?

Yes, serious allergic reactions, including hypersensitivity, anaphylactoid reactions, and anaphylactic shock, are documented as potential undesirable effects in the official product information. These conditions are serious and should be addressed promptly by a healthcare professional.

Q: What are the main conditions Pentaglobin is approved to treat?

Regulatory documents indicate the medicine is used for conditions requiring Immunoglobulin Substitution (such as Primary Immunodeficiency) and for severe acute conditions like Severe Bacterial Infections. The medicine is also evaluated in research for its use in Severe Sepsis and Septic Shock, for which study results have varied.

Q: Does Pentaglobin require special monitoring after administration?

Regulatory documents identify certain populations, such as older adults and those with pre-existing kidney issues, as needing specific consideration and monitoring during and after administration. This is due to the documented risk of serious, though rare, events like acute renal failure and blood clots.

Q: What does 'Human Normal Immunoglobulin' mean on the label?

The term indicates that the medicine is derived from pooled human plasma, containing a broad spectrum of protective antibodies (IgG, IgA, IgM) similar to those found in healthy individuals. This composition is intended to provide immediate passive support to the patient's immune system.

Q: What should I tell my doctor before starting Pentaglobin?

The prescribing information indicates that a doctor should be aware of any pre-existing medical conditions, including any known allergies, especially severe allergy to immunoglobulins or anti-IgA antibodies. Additionally, factors like a history of blood clots or pre-existing kidney conditions are noted as factors that may require specific monitoring during treatment.

Q: Why are people sometimes pre-treated with medicines before getting Pentaglobin?

The regulatory information indicates that many non-serious side effects, such as fever or chills, can occur and may be related to the rate of infusion. The management of infusion-related reactions may include the use of pre-treatment, which is a method employed by healthcare professionals.

Q: How does the manufacturing process ensure the product is safe?

The medicine is a biological product derived from human plasma, and its safety relies on rigorous processes including donor screening, quality testing, and plasma fractionation. These processes ensure the product meets high regulatory standards and includes steps established to reduce the risk of viral pathogen transmission.

Q: Are there specific symptoms that mean a side effect is serious?

The official product information lists serious, though rare, conditions such as Anaphylactic shock, Acute Renal Failure, and Thromboembolic events (blood clots). Symptoms that may suggest a serious reaction require prompt attention by a healthcare professional.

Q: Is the use of Pentaglobin supported by major medical guidelines?

The clinical role of immunoglobulin replacement therapy is widely supported by long-standing consensus among the medical community, and the World Health Organization (WHO) classifies this type of medicine as essential. While evidence for certain acute uses is noted as mixed, the therapy is recognized as vital for providing immediate antibody support.

Q: Does Pentaglobin treat the underlying cause of infection or just the symptoms?

The primary role of the medicine is to provide immediate passive immunity by delivering protective antibodies that neutralize pathogens, bacterial toxins, and inflammatory mediators. This action supports the body's immune defense mechanisms, helping to control the systemic microbial threat.

Advertisements

How should Pentaglobin (Human Normal Immunoglobulin) be stored and disposed of?

Storage and Disposal of Pentaglobin (Human Normal Immunoglobulin)

Pentaglobin must be stored strictly according to the official regulatory requirements to maintain its stability.

  • Required Temperature: The product must be stored in a refrigerator at a temperature between +2 °C and +8 °C. This controlled cold-chain storage ensures a labeled shelf-life of 2 years.
  • Protection Conditions: It is mandatory to not freeze the solution, and solutions that have been frozen must not be used. The product should also be stored away from light.
  • Handling Prior to Use: Before infusion, the solution should be allowed to warm up to room temperature or body temperature. The solution must be visually inspected for any particles or discoloration before administration.
  • Child Safety: This medicine must be kept out of the sight and reach of children.
  • Disposal: Disposal of any unused Pentaglobin or waste material must be carried out according to local requirements for pharmaceutical waste, and it should not be discarded in household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pentaglobin (Human Normal Immunoglobulin) found in:

A-Z Index: